文献速递物质与行为成瘾

心率变异性生物反馈治疗物质使用障碍的随机临床试验

Heart Rate Variability Biofeedback for Substance Use Disorder: A Randomized Clinical Trial.
PubMed 文献 · JAMA Psychiatry · 2025-01-01

这项在美国开展的2期随机临床试验纳入120名寻求治疗的物质使用障碍成人,评估第二代可穿戴心率变异性生物反馈(HRVB)联合常规治疗(TAU)与仅TAU相比,对负性情感、正性情感、渴求及酒精和其他药物(AOD)使用的影响。结果显示HRVB组负性情感和渴求显著降低,AOD使用天数比例显著降低,且HRVB削弱了渴求与后续AOD使用之间的关联。

要点

  • HRVB联合TAU可显著降低物质使用障碍患者的负性情感和渴求。
  • HRVB组AOD使用天数比例显著低于对照组,约减少64%。
  • HRVB可能通过削弱渴求与后续使用之间的关联发挥作用。

核心结论

  • 第二代HRVB可降低早期康复期物质使用障碍患者的负性情感、渴求及物质使用,部分通过打断渴求与后续AOD使用的关联实现。

研究设计与样本

  • 2期随机临床试验,8周门诊治疗,2023年2月至2024年6月在全美虚拟招募寻求治疗的物质使用障碍成人。
  • 共评估260人,随机120人至HRVB+TAU组或仅TAU组。
  • 参与者中女性69/115(60.0%),平均(SD)年龄46.18(11.59)岁。

主要发现

  • HRVB与8周内负性情感显著降低相关(b,-0.01;z,-3.21;P=.001),而对照组负性情感增加。
  • HRVB与8周内渴求显著降低相关(b,-0.01;z,-4.60;P<.001),而对照组渴求增加。
  • 正性情感未观察到组间差异。
  • HRVB与AOD使用天数比例显著降低相关(OR,0.36;95% CrI,0.25-0.54),相当于较对照组减少64%。
  • 治疗条件调节渴求与后续AOD使用的个体内关系(OR,0.84;95% CrI,0.73-0.97),HRVB组在渴求后使用AOD的可能性更低(b,-0.18;95% CrI,-0.32至-0.03)。

临床怎么用

  • HRVB可作为物质使用障碍早期康复的辅助治疗,与常规治疗联合使用可能减少负性情感、渴求及物质使用。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Preliminary studies suggest heart rate variability biofeedback (HRVB) may reduce craving and negative affect in individuals with substance use disorder (SUD), but few studies have evaluated whether this translates into improved substance use outcomes, and no prior studies have examined second-generation wearable HRVB technology in this context. OBJECTIVE: To evaluate the effects of second-generation HRVB on negative affect, positive affect, craving, and alcohol and other drug (AOD) use in adults with SUD. DESIGN, SETTING, AND PARTICIPANTS: This phase 2 randomized clinical trial included 8 weeks of outpatient treatment. Recruitment was conducted virtually across the US from February 2023 to June 2024. Treatment-seeking adults with SUD were randomized to receive HRVB + treatment as usual (TAU) or TAU only. INTERVENTION: Eight weeks of HRVB. MAIN OUTCOMES AND MEASURES: The primary outcomes were negative affect, positive affect, craving, and substance use, assessed with ecological momentary assessment. RESULTS: Of 260 individuals assessed for eligibility, 120 were randomized to receive HRVB + TAU or TAU only. Among study participants (69 female participants of 115 [60.0%]; mean [SD] age, 46.18 [11.59] years), HRVB was associated with significant reductions in negative affect (b, -0.01; z, -3.21; P = .001) and craving (b, -0.01; z, -4.60; P < .001) over 8 weeks. In contrast, the control group experienced increases in both negative affect and craving. No differences were observed for positive affect. HRVB was also associated with a significantly lower proportion of AOD use days (odds ratio [OR], 0.36; 95% credible interval [CrI], 0.25-0.54), representing a 64% reduction in AOD use compared to controls. Treatment condition moderated the within-person relationship between craving and later AOD use (OR, 0.84; 95% CrI, 0.73-0.97), such that those receiving HRVB were less likely to use AOD following craving (b, -0.18; 95% CrI, -0.32 to -0.03). CONCLUSIONS AND RELEVANCE: In this randomized clinical trial, findings suggest second-generation HRVB can reduce negative affect, craving, and substance use among individuals in early recovery from SUD. HRVB appears to confer benefit in part by disrupting the association between craving and subsequent AOD use; these results support HRVB as a potentially efficacious treatment for SUD and warrant further investigation in phase 3 trials. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05454657.

来源:JAMA Psychiatry,查看原文。版权归原作者所有。

引用

  1. Eddie D, Nguyen M, Zeng K, et al. Heart Rate Variability Biofeedback for Substance Use Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2025. PMID: 41032322. doi:10.1001/jamapsychiatry.2025.2700

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。